Last reviewed · How we verify

NCT04697979: REMEDIPA

Post-Stroke Medication Relay

Completed Last updated 18 March 2026
What this trial tests

trial testing Questionnaire in Stroke, Ischemic in 54 participants. Completed in 27 April 2022.

Timeline
11 March 2021
Primary endpoint
27 April 2022
27 April 2022

Quick facts

Lead sponsorHospices Civils de Lyon
StatusCompleted
Study typeOBSERVATIONAL
Enrollment54
Start date11 March 2021
Primary completion27 April 2022
Estimated completion27 April 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Stroke, Ischemic or Medication Compliance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prior to discharge from hospital and return home, patients managed for ischemic stroke will receive a pharmaceutical interview to discuss their discharge prescription (indication, method of administration, precautions, and possible side effects). Improvements in the use of medications in the community and in hospital follow-up. Telephone interviews or teleconsultations will make it possible to assess the patient's knowledge of his or her treatment and to re-explain it if necessary to improve patient compliance with treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other recruiting trials for Stroke, Ischemic

Currently open trials in the same condition.

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04697979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing